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Australia.The need for new antimalarials is persistent due to the emergence of drug resistant parasites. Here we aim
to identify new drug targets in Plasmodium falciparum by phylogenomics among the Plasmodium spp. and
comparative genomics to Homo sapiens. The proposed target discovery pipeline is largely independent of
experimental data and based on the assumption that P. falciparum proteins are likely to be essential if (i)
there are no similar proteins in the same proteome and (ii) they are highly conserved across the malaria
parasites of mammals. This hypothesis was tested using sequenced Saccharomycetaceae species as a
touchstone. Consecutive ﬁlters narrowed down the potential target space of P. falciparum to proteins that
are likely to be essential, matchless in the human proteome, expressed in the blood stages of the parasite,
and amenable to small molecule inhibition. The ﬁnal set of 40 candidate drug targets was signiﬁcantly
enriched in essential proteins and comprised proven targets (e.g. dihydropteroate synthetase or enzymes
of the non-mevalonate pathway), targets currently under investigation (e.g. calcium-dependent protein
kinases), and new candidates of potential interest such as phosphomannose isomerase, phosphoenolpyr-
uvate carboxylase, signaling components, and transporters. The targets were prioritized based on drugga-
bility indices and on the availability of in vitro assays. Potential inhibitors were inferred from similarity to
known targets of other disease systems. The identiﬁed candidates from P. falciparum provide insight into
biochemical peculiarities and vulnerable points of the malaria parasite and might serve as starting points
for rational drug discovery.
 2012 Australian Society for Parasitology Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Drug discovery programs launched by the Medicines for Malaria
Venture and other product-development partnerships have culmi-
nated in the development of promising new antimalarial com-
pounds such as the synthetic peroxide OZ439 (Charman et al.,
2011) and the spiroindolone NITD 609 (Rottmann et al., 2010),
which are currently undergoing clinical trials. In spite of these
recent successes, it is pivotal to maintain early phase drug discov-
ery to prevent the antimalarial drug development pipeline from
draining. Due to the propensity of the parasite to become
drug-resistant (Muller and Hyde, 2010; Sa et al., 2011), the need
for new antimalarial chemotypes will persist until the human-
pathogenic Plasmodium spp. are eventually eradicated.Published by Elsevier Ltd.
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Open acRational post-genomic drug discovery is based on the screening
of large chemical libraries – either virtually or in high-throughput
format – against a given target enzyme of the parasite. A persistent
bottleneck for target-based approaches is the identiﬁcation of a
suitable drug target in the ﬁrst place. This enzyme should be essen-
tial for survival of the parasite and sufﬁciently different from its
closest counterpart in the human host to be inhibited selectively.
Experimental tools to validate candidate drug targets are limited
for the malaria parasites. Gene silencing by RNAi does not seem
to be feasible (Baum et al., 2009). Gene replacement with select-
able markers is (Triglia et al., 1998), but it is inherently problem-
atic to call a gene essential from failing to knock it out. Inducible
degradation of Plasmodium falciparum proteins that have been
fused to a FKBP-destabilization domain (Armstrong and Goldberg,
2007) is currently the most conclusive method for antimalarial
target validation. However, none of the reverse genetic methods
is practicable at the genome-wide scale. Adding up to the chal-
lenges with Plasmodiummolecular biology is the lack of a phyloge-
netically close model organism that could serve as a point of
reference – as is the case with parasitic nematodes, where essenti-
ality of genes may be estimated based on the RNAi phenotypes
(Schindelman et al., 2011) of orthologues in Caenorhabditis elegans.cess under CC BY-NC-ND license.
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ployed to help identify or prioritize drug targets for Plasmodium
parasites. These include techniques based on automated identiﬁca-
tion of important steps in metabolic pathways (Yeh et al., 2004;
Fatumo et al., 2009; Huthmacher et al., 2010; Plata et al., 2010),
techniques that combine chemical starting points and protein-
based queries (Joubert et al., 2009), as well as the use of the TDR-
targets web-resource (http://www.tdrtargets.org) (Magarinos
et al., 2012) to prioritize drug targets through the combination of
multiple data types relevant to drug development (Crowther
et al., 2010).
Here we try to predict antimalarial drug targets in silico, build-
ing on previous approaches by other labs for predicting essentiality
of proteins based on phylogeny (Doyle et al., 2010; Waterhouse
et al., 2010). We deﬁne a protein as a candidate antimalarial
drug target if it (i) has conserved orthologues in all of the mamma-
lian-pathogenic Plasmodium spp.; (ii) has no other match in
P. falciparum; (iii) does not have a good match in the human prote-
ome either; (iv) is expressed in the trophozoite and gametocyte
stages; and (v) is predicted to function as an enzyme, receptor, or
transporter. The rationale is that conserved genes often fulﬁll
essential functions – or rather that genes fulﬁlling essential func-
tions are under negative selection. A conserved single copy gene
that lacks close matches in the same genome is likely to be
indispensable. Starting from the complete predicted proteome of
P. falciparum (Gardner et al., 2002), we applied consecutive ﬁlters
to extract all candidate drug targets that meet the above criteria.407 (14%) essential proteins698 (24%)
200
150
S. cerevisiae
n = 5,887
1002. Material and methods
2.1. Datasets
The predicted Plasmodium spp. proteomes were downloaded
from PlasmoDB (http://www.plasmodb.org/common/downloads)
(Aurrecoechea et al., 2009), the Saccharomyces cerevisiae proteome
from SGD (Saccharomyces genome database; http://www.down-
loads.yeastgenome.org/) (Engel et al., 2010), the Homo sapiens pro-
teome from EBI (ftp://www.ftp.ebi.ac.uk/pub/databases/integr8/
fasta/proteomes) (Mulder et al., 2008), and all others from UniProt
(http://www.uniprot.org/taxonomy) (Magrane and Consortium,
2011). P. falciparum 3D7 cell cycle expression data (Le Roch et al.,
2003) were obtained from PlasmoDB, using as a threshold for
expression E > 10 and probe signal distribution logP < 0.5 as pro-
posed by the authors (Le Roch et al., 2003). S. cerevisiae deletion
phenotype data were from SGD (http://www.downloads.yeastge-
nome.org/curation/literature/phenotype_data.tab). Proteins were
termed essential if the phenotype of the knock-out (mutant
type = ‘null’) of the corresponding gene was ‘inviable’. The TDRtar-
gets web resource (http://www.tdrtargets.org) (Magarinos et al.,
2012), as well as the BRENDA database (http://www.brenda-enzy-
mes.org) (Scheer et al., 2011) was used to identify proteins with
precedence for interaction with small molecule chemical inhibi-
tors. Essentiality of Plasmodium berghei orthologues was found
through RMgmDB (Rodent Malaria genetically modiﬁed Parasites;
http://www.pberghei.eu/) (Janse et al., 2011).50
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Fig. 1. S. cerevisiae non-redundant proteins. Frequency distribution of the similar-
ities for all predicted S. cerevisiae proteins to their next best match in the same
proteome. Of the 1109 essential proteins, 698 were below the median identity of
15.7% (red bar) and 407 above (4 proteins had exactly 15.7% identity to their next
best match). The black area represents the proteins below the threshold of 615%
global identity. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)2.2. Programs
InParanoid was obtained from http://www.inparanoid.sbc.su.se
and QuickParanoid from http://www.pl.postech.ac.kr/QuickPara-
noid. BLAST 2.2.17 (Altschul et al., 1990) was downloaded from
NCBI (ftp.ncbi.nlm.nih.gov), Needle (from the EMBOSS suite (Rice
et al., 2000)) from http://www.emboss.sourceforge.net. All pro-
grams were run on the Basel Biocomputing Linux cluster (http://
www.bc2.unibas.ch).2.3. Algorithms
The pipeline for comparative genomics and target prediction
was run in a semi-automated way, combining the existing pro-
grams (see Section 2.2) with self-made Perl scripts for parsing,
re-formatting, and analysis of outputs. Druggability scores were
extracted from the TDRtargets website (Magarinos et al., 2012).
These druggability predictions are numerical values between 0
and 1, with 1 corresponding to more druggable targets. Scores re-
ﬂect a combination of factors including degree of similarity to a
large library of targets within the ChEMBL database (Hopkins
et al., 2011; Gaulton et al., 2012), with empirically determined
interactions with drug like compounds, possession of physiochem-
ical features enriched in known drug targets, and the drug-like
quality of the inhibitors known to interact with those homologues.
These scores are outputs of a combination of multiple discrimina-
tors based on empirically-characterized drug targets, but are
untested in Plasmodium, other than through concordance of high-
scoring proteins with the very few known antimalarial drug tar-
gets. Proteins with higher druggability scores are likely to be more
amenable to inhibition with drug-like molecules than proteins
with low druggability scores, and hence are used here as one
aspect of the ranking system, but there is lack of parasite-speciﬁc
direct data for these algorithms with which to assign a cutoff for
designating an acceptable score.3. Results and discussion
3.1. Using yeast as a touchstone for essentiality prediction
The central hypothesis implemented in the present target dis-
covery pipeline is, that a protein is likely to be essential if there
are no other similar proteins in the same proteome but conserved
orthologues in all the related species. Before applying it to malaria
parasites, we tested the hypothesis on the yeast S. cerevisiae where
essentiality of proteins has been tested by systematic knock-out of
the respective genes (Winzeler et al., 1999). The current null mu-
tant dataset in the Saccharomyces Genome Database comprises
5477 genes, of which 1109 were found to be essential. To test
whether a given S. cerevisiae protein is unique, its best match
(excluding itself) in the same proteome was identiﬁed with Blastp
(Altschul et al., 1990), then and a Needleman-Wunsch global align-
ment (Needleman and Wunsch, 1970) was performed between the
two proteins. The median global identity between a S. cerevisiae
protein and its best match was 15.7% (red bar in Fig. 1). 14% of
the proteins with a match above the median were essential, com-
pared to 24% of those below the median (Fig. 1). The difference was
Table 1
Proteomes used in this study, their sizes and sources.
Species Proteins Source Version
P. falciparum 5410 PlasmoDB 8.1
P. vivax 5396 PlasmoDB 8.1
P. berghei 4861 PlasmoDB 8.1
P. chabaudi 5119 PlasmoDB 8.1
P. knowlesi 5194 PlasmoDB 8.1
P. yoelii 7724 PlasmoDB 8.1
H. sapiens 67,172 Integr8 08/2011
S. cerevisiae 5887 SGD R64-1-1
A. gossypii 4761 UniProt 08/2011
C. albicans 5727 UniProt 08/2011
C. glabrata 5197 UniProt 08/2011
D. hansenii 6242 UniProt 08/2011
K. lactis 5074 UniProt 08/2011
Y. lipolytica 6414 UniProt 08/2011
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Fig. 3. P. falciparum non-redundant proteins. Frequency distribution of the simi-
larities for all predicted P. falciparum proteins to their next best match in the same
proteome. The median is shown in red, the black area represents the proteins
which, passing the threshold of 615% global identity, are assumed to be enriched
for essential ones.
P. falciparum
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the hypothesis that ‘unmatched’ proteins are more likely to be
essential (Hannay et al., 2008). Setting the cut-off at 615% global
identity 2648 S. cerevisiae proteins passed (black area in Fig. 1),
26% of which were essential (Fig. 2).
To determine which of the S. cerevisiae proteins are conserved
across the Saccharomycetaceae, a set of related (Fitzpatrick et al.,
2006) and fully sequenced yeasts served as the reference: Candida
glabrata, Ashbya gossypii, Kluyveromyces lactis, Candida albicans,
Debaryomyces hansenii, and Yarrowia lipolytica. The predicted pro-
teomes (Table 1) were fed into InParanoid and QuickParanoid
(Ostlund et al., 2010), programs that utilize reciprocal, proteome-
wide Blastp searches to build groups of orthologous proteins and
rank them. A total of 3546 S. cerevisiae proteins possessed ortho-
logues in all the included yeasts. The highly conserved orthology
clusters, i.e. those above median similarity, were signiﬁcantly en-
riched for essential proteins (Fig. 2): 29% of the S. cerevisiae pro-
teins that belonged to a conserved cluster were essential
(p < 0.0001, two-sided Chi-square test). Finally the intersect of
the two sets, unmatched and conserved, contained 632 proteins
of which 40% were essential (Fig. 2). The yeast results supporting
our working hypothesis, we went on to apply it to malaria
parasites.
3.2. Essentiality prediction in P. falciparum
The predicted P. falciparum proteome exhibits a strikingly low
degree of redundancy, with the large majority of proteins exhibit-
ing but a low level of similarity to their next best match in the
same proteome (Fig. 3). As described above (Section 3.1) for S. cere-
visiae, the closest hit to any P. falciparum protein was determined
with Blastp. Similarity was measured by global alignment and ex-
pressed as percent identical amino acids. The median global iden-
tity between a P. falciparum protein and its next best match was
only 13% (red bar in Fig. 3), and 3078 of the 5410 proteins passed
the threshold of 615% global identity to their next best match
(black area in Fig. 3).
The conserved Plasmodium proteins were identiﬁed by compar-
ing P. falciparum to all other available genome sequences of mam-
malian malaria parasites, namely P. berghei, Plasmodium chabaudi
and Plasmodium yoelii (mouse), Plasmodium knowlesi (primate),
and Plasmodium vivax (human tertian malaria). The six genomes
encode a total of 33,704 predicted proteins (Table 1). The common
intersect of proteins from orthology clusters represented in all theSaccharomyces cerevisiae
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S cerevisiae proteome 5 477 1 109 20%. , ,
Unmatched >15% global identity 2,648 677 26%
Conserved in Saccharomycetaceae 1,773 514 29%
Unmatched & conserved 632 253 40%
Fig. 2. Testing for essentiality with yeasts. The cladogram depicts the phylogeny of
the fully sequenced Saccharomycetaceae (Fitzpatrick et al., 2006). Eliminating the S.
cerevisiae proteins which possess matches in the same proteome (gray area in
Fig. 1), and those which are not conserved across all the analyzed yeasts, enriches
for essential proteins.six species was 26,377, as determined with InParanoid and Quick-
Paranoid (Ostlund et al., 2010). This amounts to 78% of all proteins,
reﬂecting the close relationship of the malaria parasites. The num-
ber of proteins in the common clusters was conserved in all theSpecies-specif ic proteins
Only in the Plasmodium spp. of  rodents
Only in the Plasmodium spp. of  primates
In all six Plasmodium spp. analyzed
Irregular distribution of  orthologues
P. knowlesi
P. vivax
P. berghei
P. yoelii
P. chabaudi
Fig. 4. The conserved malaria proteome. The cladogram depicts the phylogeny of
the fully sequenced malaria parasites of mammals (Martinsen et al., 2008). The bars
divide each predicted proteome into proteins present only in the species itself,
proteins with orthologues only in the Plasmodium spp. sharing intermediate hosts,
and proteins with orthologues in all the analyzed species (3610 in P. falciparum).
The white sections represent proteins with an irregular distribution insofar as the
presence of orthologues did not correlate with host speciﬁcity (nor with
phylogeny).
Total proteome 5,410
Conserved in Plasmodium spp. 944
No good match in the human proteome 426
Expressed in the asexual erythrocytic stages 288
Predicted function as enzyme, receptor, transporter 40
3,078Unique in P. falciparum
Fig. 6. From genome to target. Overview on the in silico pipeline to narrow down
the potential target space of P. falciparum. The 40 identiﬁed candidates are listed in
Table 2.
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lated with the number of species-speciﬁc proteins (Fig. 4). Of the
5410 predicted P. falciparum proteins, 3610 (67%) possessed at
least one orthologue in all of the other Plasmodium species
(Fig. 4). 630 P. falciparum proteins did not have an orthologue in
any other species and 139 had an orthologue in P. vivax and P.
knowlesi but not in the malaria parasites of rodents (Fig. 4). The dif-
ferent protein subsets outlined in Fig. 4 for each parasite are avail-
able as a Supplementary excel ﬁle (supplement1.xls). The intersect
of the two subsets, P. falciparum unique (n = 3078) and P. falcipa-
rum highly conserved (i.e. above median, n = 1805), contained
944 proteins which we posit – based on the results with S. cerevi-
siae – to be enriched for essential ones.
3.3. Comparative genomics between parasite and host
For each predicted protein of P. falciparum the best match in the
human proteome was identiﬁed with Blastp, ranking the obtained
hits by ascending expectancy (E-values). The similarity between a
P. falciparum protein and this closest match from H. sapiens was
then quantiﬁed with a Needleman-Wunsch global alignment
(since the local alignment provided by Blast may be misleading if
the similarity between two otherwise unrelated proteins is con-
ﬁned to a smaller common domain). The frequency distribution
of global identity to human proteins in the P. falciparum proteome
is shown in Fig. 5. The most conserved proteins between parasite
and host were ubiquitins, histones, calmodulin, and tubulin. The
median global identity between a P. falciparum protein and its best
match in H. sapiens was 10% (red bar in Fig. 5). Proteins exhibiting
>10% identity to the host (gray area in Fig. 5) were removed from
the potential target space, which thereby was trimmed down to
426 proteins (Fig. 6). Some of these still had highly signiﬁcant
Blastp E-values to a human protein, e.g. the P. falciparum kinases
listed in Table 2, since a short region of high similarity in two
otherwise disparate proteins can return a high local alignment
score (in the case of the P. falciparum kinases, this region is the cat-
alytic domain). Nevertheless, selective targeting might be possible
against other domains.
3.4. Blood-stage expression of putative targets
The majority of genes in P. falciparum are expressed in a stage-
dependent manner (Llinas and DeRisi, 2004), and it is in the asex-
ual and gametocyte stages that we attempt to ﬁnd targets given
their roles in pathology and transmission. We relied on a published
microarray dataset (Le Roch et al., 2003) of P. falciparum cultures
synchronized by sorbitol treatment to identify the potential targets
that are present in the blood stages. Retaining only the products of
genes which are expressed in the ring stages, trophozoites, or
schizonts, reduced the target space to 288 proteins (Fig. 6). The100
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Fig. 5. Parasite vs. host. Frequency distribution of percent global identity to H.
sapiens in the P. falciparum proteome. The red bar marks the median, the gray areas
the P. falciparum proteins that were excluded from the potential target space.complete list is available as a Supplementary excel ﬁle (supple-
ment2.xls). Over half of these (n = 178) could not be assigned a
putative function. Although of potential interest since conserved
in the malaria parasites and absent in humans, these proteins were
(for the time being) removed from the candidate target set. Other
proteins were removed manually because they were not likely to
have a function that is susceptible to inhibition, e.g. structural pro-
teins or surface antigens. Focusing on proteins with a clear, though
sometimes putative, functional annotation in PlasmoDB as en-
zyme, receptor or transporter resulted in a ﬁnal set of 40 P. falcipa-
rum candidate drug targets (Fig. 6).3.5. Assessing essentiality of the 40 identiﬁed candidate targets
For four of the predicted essential proteins attempts have been
made to disrupt the corresponding gene in P. falciparum (Table 3).
In three cases disruption was attempted through deletion by
recombination but no gene deletion could be obtained (Santiago
et al., 2004; Wang et al., 2004; Abdi et al., 2010). For the fourth
gene ispH (HMBPP reductase; PFA0225w), introduction of a ham-
merhead ribozyme targeting the transcript was lethal (Vinayak
and Sharma, 2007). Thus, each of these four genes experimentally
examined appeared to be essential. Similarly, a small number of
these proteins’ orthologues in P. berghei or Toxoplasma gondii have
been the subject of directed gene knock-out or mutagenesis
experiments aimed at assaying their essentiality. The orthologues
of the kinases PF13_0166 and CDPK7 (PF11_0242) have been sug-
gested to be essential in P. berghei (Tewari et al., 2010). In T. gondii,
the orthologue of the apurinic/apyrimidinic endonuclease
(PF13_0176) has been shown to essential by conditional knockout
(Onyango et al., 2011) and GAP40 (PFE0785c) is part of the essen-
tial glideosome complex, though the protein itself has not been
veriﬁed as essential (Frenal et al., 2010). Only one gene was found
to be non-essential. The P. berghei CDPK6 (PF11_0239) orthologue
has been successfully deleted by double crossover (Coppi et al.,
2007). These experimental assays for essentiality thus indicate
eight of the predicted proteins to be essential, and only one to be
non-essential, supporting our method to enrich for essentiality.3.6. Prediction of druggability
In order to recognize the important role of chemical accessibil-
ity in ranking of putative drug targets we looked for druggability
information on the predicted essential targets. Druggability de-
scribes the properties of a protein that make them able to interact
with a drug-like molecule. Some proteins have physiochemical and
structural properties that make them unlikely to ever bind a com-
pound with the necessary characteristic to be a drug, and whole
genome analyses have estimated that only 10% of a genome may
represent druggable proteins (Hopkins and Groom, 2002). As part
Table 2
Forty candidate drug targets from P. falciparum identiﬁed as outlined in Fig. 6, their putative function, Blastp E-value to the best hit in the human proteome, and druggability index
(D.I.). The categories (italics) are arbitrary and mainly meant to illustrate the functional diversity of the identiﬁed targets.
Accession Putative function %Id Hsa E Hsa D.I.
Metabolism
PF08_0095 Dihydropteroate synthetase (2.5.1.15) 0.8 8.5 0.8
MAL8P1.156 Mannose-6-P isomerase (5.3.1.8) 6.9 1E-8 0.6
PF08_0068 FAD-dependent monooxygenase 6.0 0.07 0.5
PF14_0334 Ornithine aminotransferase (2.6.1.13) 4.3 1E-14 0.3
PF13_0234 PEP carboxykinase (4.1.1.49) 4.0 3.6 0.2
PF14_0246 PEP carboxylase (4.1.1.31) 3.8 4.5 0.1
PFI1180w Patatin-like phospholipase 6.3 7.4 0.1
PF10_0221 HMB-PP synthase (GcpE, 1.17.7.1) 6.5 2.2
PFA0225w HMB-PP reductase (1.17.1.2) 7.3 5.3
MAL7P1.88 Thioredoxin-like protein 3.1 4.9
PFI1340w Fumarate hydratase (Fumarase, 4.2.1.2) 10.0 2.7
PF08_0132 Glutamate dehydrogenase C (1.4.1.2) 8.1 7.2
PFD0285c Lysine decarboxylase (4.1.1.18) 5.6 7.4
PFL0620c Glycerol-3-P acyltransferase (2.3.1.15) 9.8 1.0
PF14_0250 Lipase 3.3 8.1
Nucleic acids
PF14_0273 RNA methyltransferase 9.8 7E-30 0.7
PF13_0080 Telomerase reverse transcriptase (2.7.7.49) 0.3 0.04 0.5
PF13_0176 Apur./apyr. endonuclease (4.2.99.18) 2.6 2.6 0.2
MAL13P1.311 Exonuclease 5.9 7E-4 0.1
MAL13P1.328 DNA topoisomerase VI, b subunit 4.9 7.1
PFE0675c DNA photolyase (4.1.99.3) 3.7 0.06
PF13_0048 NUDIX hydrolase (3.6.1.17) 8.4 8E-35
PF08_0111 RNA helicase 7.8 8E-15
PFC0980c RNA triphosphatase 8.5 8.6
Signaling
PF11_0239 Ca2+-dependent protein kinase 6 7.8 9E-34 0.5
PF11_0242 Ca2+-dependent protein kinase 7 9.0 6E-41 0.5
PF13_0258 Serine/threonine protein kinase TKL3 4.8 3E-21 0.5
PFA0515w Phosphatidylinositol-4-P-5-kinase (2.7.1.68) 7.0 1E-24 0.5
PF13_0166 Protein kinase 8.9 7E-4 0.3
PF07_0024 Inositol phosphatase 7.3 1E-31 0.3
MAL7P1.18 Serine/threonine protein kinase 4.7 5E-13 0.1
MAL7P1.64 G protein-coupled receptor 2.5 93 0.1
PF14_0143 Atypical protein kinase, ABC-1 family 3.8 4E-26
PF14_0614 Phosphatase 6.1 4E-5
Protease/chaperone
PF14_0382 Stromal-processing peptidase 4.4 0.001 0.5
PF10_0032 DnaJ protein 2.4 7E-4
Transporter
PF11_0092 Mechanosensitive ion channel 5.0 11 0.1
PF13_0019 Na+:H+ antiporter 6.6 0.01 0.1
PFI0785c Sugar transporter 2.8 0.09 0.1
PFE0785c Metabolite transporter/glideosome component 0.7 10
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zymes from the P. falciparum proteome (Aguero et al., 2008; Mag-
arinos et al., 2012). This score predicts the suitability of the protein
for binding a drug like molecule, and is an aggregate of several fac-
tors including physiochemical and structural features of the pro-
tein and sequence similarity to validated druggable proteins from
other organisms (Al-Lazikani et al., 2007; Gaulton et al., 2012). Of
the 40 targets predicted as essential, 23 have positive druggability
scores (Table 2). Those with the highest scores are predicted to
have more druggable structures and might therefore be prioritized
over potential targets with low or zero druggability scores. The
higher druggability scores are more likely to be indicative of prom-
ising drug target-like proteins, but any positive score indicates
structural or physiochemical similarity to proteins with some pre-
cedence for interaction with a drug-like molecule.
To search for proteins with speciﬁc compounds as starting
points for inhibitor development we also searched for proteins that
had been identiﬁed as the targets of inhibitors, or that had ortho-
logues with identiﬁed inhibitors. Searches were conducted of the
TDRTargets database, the ChEMBL database and the BRENDA data-
base to identify such targets. Of the 40 predicted essential P. falci-
parum genes, 2 have been directly validated as the targets ofinhibitors. One of these, dihydropteroate synthetase (DHPS;
PF08_0095) is one of the very few validated targets of clinically
used antimalarials, consistent with the value of our approach for
identifying essential targets. An additional 13 proteins have ortho-
logues with identiﬁed small molecule inhibitors. Identiﬁcation of
these inhibitors not only provides useful starting points for identi-
fying small molecules with which to interrogate the Plasmodium
targets, but also indicates that these are likely to be potentially
druggable targets. Compounds were curated to exclude facile
inhibitors such as natural amino acids, ATP and NaCl, however
no systematic attempt was made to rate the drug-like quality of
the predicted inhibitors. For the kinases in the list a slightly mod-
iﬁed approach was taken, as many kinase inhibitors are well
known to be cross reactive against multiple kinases. An empirical
cut-off of 30% local sequence identity in the kinase domains was
therefore used to identify homologues for potential inhibitors of
from the TDR/ChEMBL data (Table 3).
3.7. Experimental amenability of the predicted targets
Tractability of a target for developing an assay in which inhibi-
tion is a major factor in prioritizing promising drug targets in
Table 3
Identiﬁed targets, evidence for essentiality in apicomplexan parasites (Pfa, P. falciparum; Pbe, P. berghei; Tgo, T. gondii), known and inferred inhibitors, and published in vitro
assays.
Accession Enzyme Essentiality Inhibitors Assay References
PF08_0095 DHPS Pfa Sulfonamides Yes Wang et al. (2010)
PF14_0273 RNA
methyltransferase
8 inferred Yes Riguet et al. (2005), Leber et al. (2009)
MAL8P1.156 M6P isomerase 8 Wells et al. (1995), Salvati et al. (2001) and Foret et al. (2009)
PF11_0242 CDPK7 Pbe 72 inferred 12 Publications
PF11_0239 CDPK6 Not in Pbe 2488
inferred
189 Publications
PFA0515w PI-4-P-5-kinase 1 Kobayashi et al. (2005) and Santiago et al. (2004)
PF13_0080 Telomerase RT Berberine Sriwilaijareon et al. (2002)
PF13_0258 TKL3 Pfa Yes Abdi et al. (2010)
PF13_0166 Protein kinase Pbe
PF14_0334 OAT >10 Yes Strecker (1965), Levillain et al. (2000), Wang et al. (2007), Stranska et al. (2008) and Gafan
et al. (2001)
PF13_0176 AP endonuclease Tgo >20 Yes Onyango et al. (2011), Zawahir et al. (2009), Bapat et al. (2010), Adhikari et al. (2012) and
Haltiwanger et al. (2000)
PF13_0234 PEP
carboxykinase
Yes Hayward (2000)
PF14_0246 PEP carboxylase 9 Yes Pairoba et al. (1996), McDaniel and Siu (1972) and Jenkins (1989)
PFD0285c Lysine
decarboxylase
4 Yamamoto et al. (1991) and Takatsuka et al. (1999)
PFI1340w Fumarase 2 Yes Flint (1994), Beeckmans and Van Driessche (1998) and Bulusu et al. (2011)
PFL0620c G3P
acyltransferase
Pfa >40 Yes Santiago et al. (2004), Yamashita and Numa (1981), Coleman (1988) and Wydysh et al.
(2009)
PF13_0048 NUDIX hydrolase >20 Guranowski et al. (2003, 2009) and Branson et al. (2009)
PF08_0132 GDH C >20 Yes Li et al. (2007, 2009), Rodriguez-Acosta et al. (1999)
PFA0225w HMB-PP
reductase
Pfa Yes Vinayak and Sharma (2007) and Rohrich et al. (2005)
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compared to those working on human proteins, means fewer pro-
tein reagents are available. This is exacerbated in malaria research
because the P. falciparum genome is extremely A + T rich, and many
proteins have long low-complexity insertions, making recombi-
nant protein production challenging. High throughput attempts
to generate recombinant Plasmodium enzymes have relatively high
failure rates (Abdi et al., 2010), so the presence of an existing assay
is a particularly relevant criteria for target prioritization. We there-
fore prioritized proteins where researchers had already developed
a direct in vitro assay for the P. falciparum enzyme. Eleven of the 40
predicted essential enzymes have had in vitro assays described in
P. falciparum, although in some cases these may not be readily
amenable to high throughput inhibitor screening.
3.8. Candidate antimalarial drug targets
The approach presented here, although starting from the com-
plete proteome, is by no means all-embracing in the sense that it
would discover every potential drug target. Many essential pro-
teins and known drug targets were missed, such as P. falciparum
enzymes which possess human orthologues but exhibit exploitable
differences nevertheless. These could be differences in sequence, as
is the case with glyceraldehyde-3-phosphate dehydrogenase (Satc-
hell et al., 2005) or in regulation, as demonstrated for dihydrofolate
reductase (Zhang and Rathod, 2002). Other proven targets were
eliminated because they possess several paralogues, e.g. the falci-
pains (Teixeira et al., 2011). Using rigorous ﬁlters, we tried to max-
imize the speciﬁcity of target prediction at the cost of sensitivity,
taking into account a large number of false negatives. Our aim
was not to identify all potential antimalarial drug targets but
rather to come up with a sizeable list of promising targets that
(i) may serve as starting points for rational drug discovery and
(ii) provide new insights into peculiarities and vulnerable points
of the malaria parasites. The applied selection criteria were rigor-
ous (Fig. 6), so the list of potential targets could be expanded by
using less stringent ﬁlters. The present approach identiﬁed 40candidate drug targets from P. falciparumwhich are shown in Table
2. We are conﬁdent that this set contains promising leads because
it includes known targets such as dihydropteroate synthetase
(PF08_0095), the target of sulfonamides (dihydrofolate synthetase
is not included because it is 20% identical to human mitochondrial
tetrahydrofolylpolyglutamate synthase, EC 6.3.2.17), and enzymes
of the non-mevalonate pathway for isoprenoid synthesis. Another
potential target in the apicoplast could be stromal processing
peptidase (PF14_0382), which has already been characterized in
P. falciparum (van Dooren et al., 2002). Investigational targets iden-
tiﬁed include glutamate dehydrogenase C (PF08_0132) (Aparicio
et al., 2010; Storm et al., 2011) and Ca2+-dependent protein kinases
(PF11_0239, PF11_0242) (Kato et al., 2008; Ojo et al., 2010; Lim
et al., 2012). In addition, there are enzymes which are being tar-
geted in other systems, e.g. apurinic/apyrimidinic endonuclease
(PF13_0176) (Tell et al., 2010) or telomerase reverse transcriptase
(PF13_0080) (Chen et al., 2009) by antitumor agents, or phospho-
mannose isomerase (MAL8P1.156) by antifungals. Phosphoman-
nose is a key enzyme in yeast cell wall synthesis (Mastrolorenzo
et al., 2000; Wills et al., 2001); to our knowledge, the P. falciparum
orthologue has so far not been studied. A surprising ﬁnd in the list
of candidate targets was phosphoenolpyruvate carboxylase
(PF14_0246), the enzyme responsible for carbon ﬁxation in C4
plants. The P. falciparum orthologue was characterized and pro-
posed to ﬁx atmospheric carbon as well (McDaniel and Siu,
1972). If this process is essential, PEP carboxylase could be an
attractive target since inhibitors have been identiﬁed as C4 plant
herbicides (Madhusudana et al., 1980; Jenkins, 1989; Pairoba
et al., 1996). Further candidate targets of interest could be the
identiﬁed signaling enzymes and nutrient transporters (Table 2).
4. Conclusion
Translating a pathogen’s genome sequence into new drugs is a
key challenge to post-genomic biology. Several strategies for the
prediction of drug targets that are essential and unique to the par-
asite have been proposed (Payne et al., 2001; Joyce and Palsson,
P. Ludin et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 191–199 1972008; Holman et al., 2009; Crowther et al., 2010; Deng et al., 2010;
Doyle et al., 2010; Magarinos et al., 2012). Here we implement
phylogenomic comparison within a clade of related parasites to in-
fer on protein essentiality, rather than referring to a model organ-
ism which may be understood in detail but phylogenetically
distant to the parasites. In addition, we estimate redundancy
across the parasite’s proteome based on global alignments to quan-
tify protein similarity. Thus the proposed target identiﬁcation
pipeline does not rely on experimental data to predict essentiality,
and therefore is generally applicable. The identiﬁed candidate tar-
gets from P. falciparum are, by deﬁnition, present in all the Plasmo-
dium spp. analyzed. Conservation of targets between P. falciparum
and P. vivax is important since eventual new drugs need to be ac-
tive against both parasites. Conservation of the candidate targets
between human- and rodent-pathogenic Plasmodium spp. is desir-
able as well, since mouse models are indispensable in the drug
development process. The presented target discovery pipeline is
corroborated by the presence of known antimalarial targets in
the output list (Table 2). We hope that the newly identiﬁed candi-
date targets will support the development of novel antimalarials.
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